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 Editor, Clinical Radiology 
Dear Sir 
I would like to thank the referees for their complimentary review. 
My responses alterations are detailed below 
1 EDITOR'S COMMENTS: 
1.1 If you could please just check the refs and language that would be great. 
These have both been amended as requested. 
There are a number of places ‘word’ has suggested simplification but in most cases I think this loses 
the sense of the statement. 
1.2 Personally I would leave the figures as they are; I think the visual impact is much better than 
the written word; if you wish to shorten the text instead then fine - if not then I'm happy either way. 
I will leave to your discretion. 
I have left the figures and their captions alone and I have not substantially altered the main text. I 
am happy to do this but I am within word limit and when teaching trainees (and colleagues) I find 
that they have difficulty with these concepts so repetition is no bad thing. When I read papers I find 
it really helpful if the main text and the figures each ‘stand-alone’ provided it is not just repetition 
2 EDITORIAL OFFICE REQUIREMENTS: 
Please add your Figure Legend to the main manuscript file, beneath your References. 
Done 
3 REVIEWERS' COMMENTS: 
Reviewer #1:  
3.1 There are minor typographical errors in the main body of the review which are easily 
addressed  
Please see 1.1 
3.2 however more frequent typographical/formatting errors are noted in the references which 
require checking and amending. e.g. number 23-. Waller J, Whitaker KL, Winstanley K,Power E, 
Wardle J. A survey of womens responses to information about over diagnosis in breast cancer 
screening in Britain Br J Cancer 2014;1111:1831-1835 doi 10.1038/bjc.2014.482-2 errors in title. 
ref number 8 has an additional "and" in the title 
Please see 1.1 
3.3 Figures 2 and 3 are nice diagrammatic representations but the concepts are well explained 
in the text and I don't think they add anything to the review. 
Please see 1.2 
 
Anonymous list of revisions
Over diagnosis is the inevitable flip side of early detection resulting in unnecessary labelling of well 
women with a diagnosis of cancer and possible unnecessary treatment. 
Over diagnosis occurs because breast cancers have different rates of growth and slow growing 
cancers are preferentially detected by screening.  Some of these slow growing screen-detected 
cancers may never have been clinically apparent during an individual’s lifetime.  Evaluating the 
benefits and risks of screening are complex but this has been performed for the UK population by an 
independent review led by Professor Marmot. 
It might be possible to limit over diagnosis by Identifying women with “low risk disease” earlier 
either at the point of screening when additional investigations could be delayed (possibly for ever) 
so that they are not subjected to additional diagnostic tests, or at the point of diagnosis. Both these 
options would require major re-education of clinicians and the public who would need to accept that 
screening is ‘deliberately ignoring a cancer’ 
There is a long surgical history of reducing the burden of treatment which continues today with trials 
of management of the axilla and reducing or even omitting radiotherapy for low risk disease.   The 
Low Risk Ductal Carcinoma in situ trial (LORIS) has started to Identify a group of breast cancer 
patients who could avoid surgery and be offered active monitoring. We need to consider planning a 
similar trial for row risk invasive breast cancer.  
Abstract
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Over diagnosis: disease detected that, in the absence of screening, would not otherwise have 1 
become clinically apparent and would not have had any adverse consequences on the individual. 2 
This is a highly charged political issue to the extent that the BMJ now runs an annual international 3 
conference. (1) Dr Margaret McCarthy a Scottish General Practitioner and lead writer for the BMJ 4 
summarised the issue in 2007. ‘Too much testing of well people and not enough care for the sick 5 
worsens health inequalities and drains professionalism, harming both those who need treatment 6 
and those who don’t. (2) 7 
Screening for breast cancer continues to be mired in debate. The benefit in terms of mortality 8 
reduction seems to have been settled (3-5) even if its magnitude and who to screen is less clear. The 9 
over diagnosis debate summed up in 2009 by Gilbert Welsh (6) “the question is no longer whether it 10 
occurs but how often it occurs” has not been resolved by the ‘independent reviews’ summarised by 11 
Houssami (7) and there are continuing contradictory new publications (8,9). 12 
Why does over diagnosis occur at screening?  13 
Breast cancer is not one disease with a uniform growth rate (Figure 1).  Screening finds both fast and 14 
slow growing cancers. The periodic nature of screening means that the faster growing cancers (those 15 
with a worse prognosis that are likely to progress to metastatic disease) are less likely to be found at 16 
screening and have a greater tendency to appear between screens (interval cancers). The lower 17 
grade and slower growing cancers are much more likely to be picked up by screening; length bias. 18 
(figure 2) (10). These cancers are more likely to be over diagnosed because the preclinical, screen-19 
detected cancer is progressive but the person dies prematurely of another cause before the time at 20 
which symptoms would have occurred or the growth rate of a truly progressive cancer is not rapid 21 
enough to give rise to symptoms during the person’s life time.  It is also possible that a cancer stops 22 
growing and becomes indolent for some reason or possibly even regresses (11) but this is, to say the 23 
least, controversial (12). Additionally, the slower growing cancers tend to produce more of a stromal 24 
reaction so they are easier to perceive on mammography (13) 25 
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The paradox for the clinician providing breast screening is that detecting ‘early’ breast cancer leads 26 
to mortality reduction so they are encouraged and incentivised to find more ‘early’ cancers even if 27 
some of these might never have become clinically apparent or trouble the patient so over diagnosis 28 
and early detection are the two sides of the same coin. 29 
The difficulty for individual treating clinicians and patients is that for any one individual patient we 30 
cannot readily distinguish who has been ‘saved’ by screening and early treatment and who has been 31 
harmed by unnecessary labelling with a lifelong diagnosis, unnecessary treatment and its side effects 32 
(figure 3).  So, we are left with Gray and Raffle’s popularity paradox. “The greater the harm through 33 
over diagnosis and overtreatment from screening, the more people there are who believe they owe 34 
their health, or even their life, to the programme.” (14) 35 
Quantifying both the benefits of screening in terms of reducing mortality from breast cancer and the 36 
risk of over diagnosis is complex and over many years the discussion has become polarised with 37 
quoted rates of over diagnosis between 1 and 2% (15) and 52% (16).  The UK government responded 38 
to public pressure in October 2013 and jointly commissioned an independent review with Cancer 39 
Research UK.  This review was performed by a panel of independent experts who had never 40 
previously published about breast screening and was chaired by Prof MG Marmot (4).  41 
In theory, the debate should be relatively simple to resolve using the randomised controlled trials. 42 
The excess of cancers diagnosed into the intervention arm (screening) should be balanced by the 43 
excess of cancers in the control group after the trial has finished.  The problem is that in real-life this 44 
has never happened as screening does not stop. So, the magnitude of the effect must be 45 
“calculated” by a variety of epidemiological and statistical tools using observational data, historical 46 
data and geographical controls.  As the effect on mortality seems to continue long after the trial has 47 
ended (17) each estimate has to must decide how long to wait for the excess cancers to be balanced 48 
out.  The shorter the period (18) the larger the estimate of over diagnosis and the longer the period 49 
of surveillance the smaller the estimate (19). 50 
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It is beyond the scope of this article to consider in any detail the statistical and epidemiological 51 
complexities behind the calculations particularly as this was performed in great detail by the 52 
Marmot Review (4). 53 
Estimating the benefits of screening: 54 
How good are the estimates of benefits?  Ignoring the statistical confidence in the actual numbers, 55 
all the randomised controlled trials are old and treatment has improved so their relevance to 56 
‘today’s practice’ is debated. There are well rehearsed arguments about the randomisation 57 
methodology and imperfections and disagreements about what outcome should be measured.  The 58 
trials were initially designed and powered to measure breast cancer specific mortality but this can be 59 
biased by how accurately the cause of death is recorded and how/if this was validated. Reductions in 60 
overall mortality are very small and depend on length of follow up.  Finally, how is the risk reduction 61 
presented? Should the benefit be expressed in terms of the whole population (clearly important to 62 
any potential funders of screening), namely the benefit of sending the invitation or should the 63 
benefit be expressed in terms of actually attending the screening appointment which is higher (5). 64 
This is a figure that is of more use to the individual woman concerned about balancing the harms 65 
and benefits of attending her appointment.   66 
Estimating over diagnosis 67 
The complexity of estimating the degree of over diagnosis is even harder. Carter (20) identified four 68 
types of study: follow-up of randomised controlled trials, pathology and imaging follow up, 69 
modelling and epidemiological cohort studies.  He concluded that the need for a well-designed 70 
ecological and cohort studies in multiple settings, underpinned by internationally agreed standards 71 
and unbiased researchers.  De Gelder (21) describes seven separate methodologies: these including 72 
inclusion or exclusion of DCIS, using the screening age range or the woman’s lifetime and finally 73 
whether the rate of over diagnosis is related to the women invited, the women screened or even the 74 
cancers detected. Once again this is covered in considerable detail by the Marmot review (4).   75 
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Once a relative risk has been “agreed” then this needs to be translated to the individual screening 76 
programme and the population it serves. This will vary because of the interval between screens and 77 
the intrinsic risk of a population being offered screening. The specific risk groups selected, age and 78 
personal family history being the most obvious, but in some populations as well as opportunistic 79 
programmes background density is being used to select specific women for additional imaging (22).  80 
Finally screening   performance is dependent on the test(s) being used and the professionals 81 
implementing and interpreting them. 82 
The balance of harm and benefit. 83 
Having taken all these issues into account the Marmot review (4) came up with a set of figures 84 
specifically related to the United Kingdom based on their meta-analysis of 11 randomised controlled 85 
trials with 13 years of follow-up. They estimated a 20% (11 to 20%) reduction in breast cancer 86 
mortality for women invited to screening over a 20-year period.  By applying this reduction to the 87 
National Breast Screening Programme in the United Kingdom they estimated that one breast cancer 88 
death would be prevented for every 235 women invited to screening and that 180 women would 89 
need to be screened to prevent one breast cancer death.  The panel acknowledged that there is 90 
uncertainty around these numbers and concluded that the estimates of benefits would be in the 91 
range of one breast cancer death prevented for approximately 250 women invited.  In 2013 at the 92 
time of the report they considered that that corresponded two approximately 1300 deaths from 93 
breast cancer being prevented each year or 22,000 years of life saved.  They balanced this against 94 
the risk of over diagnosis which they estimated to be at approximately 19% of the cancers diagnosed 95 
based on a 20-year programme. 96 
This translated into notional figures for 10,000 women invited to screening from the age of 54 over a 97 
20-year period.  Estimating that 681 breast cancers (invasive and DCIS) will be diagnosed, 129 of 98 
these will represent over diagnosis and 43 deaths from breast cancer will be prevented.  99 
Page 5 of 18 
 
As well as deciding what is truly ‘balanced’ information the public understanding of over diagnosis 100 
and risk is complex (23). There is a need to provide this information in an understandable form. Fig 4 101 
(24) is one of the many pictograms available from the UK. Hersch (25) developed a similar tool and 102 
tested the effects in an Australian population. At telephone interview 3 weeks after the intervention 103 
more women receiving the tool felt able to make an informed choice when compared to the control 104 
group. The intervention also improved knowledge about screening and breast cancer risk. However, 105 
it did lead to a reduction in positive attitudes to breast screening and a reduction in the number of 106 
women intending to attend screening over the next 2 to 3 years. Longer follow up and impact on 107 
attendance is awaited. (25) 108 
The consequences of over diagnosis are the psychosocial effect of being labelled with a diagnosis of 109 
breast cancer (26) and the burden of unnecessary treatment.  The problem is that we cannot 110 
currently distinguish which of these 681 individual women diagnosed with screen detected breast 111 
cancer will be lucky enough to be one of the 43 whose death from breast cancer has been prevented 112 
and which are the 129 who have been overtreated as neither group dies from cancer.  As we have 113 
very little data on the natural history of untreated breast cancer it is a major challenge to use 114 
historical data, based on women having received conventional treatment, to separate these two 115 
groups into the ones who are cured and the ones who did not require treatment in the first place. 116 
This leaves three potential approaches,  117 
Reducing over diagnosis by 118 
  Identifying women with “low risk disease” earlier either at the point of screening when 119 
additional investigations could be delayed (possibly for ever) so that they are not subjected 120 
to additional diagnostic tests, labelled with a diagnosis of cancer and offered treatment. 121 
Reducing treatment by 122 
 De-escalation of treatment for all women or at least those perceived to be at low risk,  123 
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 Identifying a group of breast cancer patients who could avoid surgery and be offered active 124 
monitoring  125 
 126 
Reducing over diagnosis. 127 
The principle group at risk of over diagnosis is the older woman. The older the age at detection the 128 
more likely she is to have a cancer diagnosis that would either not present or not cause problems 129 
within her life.  AgeX, a nationwide cluster randomization of extending the NHS Breast Screening 130 
Programme began as a trial of additional screening at ages 47-49 and at ages 71-73, now has ethical 131 
approval to continue triennial invitations at ages 71-76 or at ages 71-79 thereby assessing the effects 132 
of continuing triennial screening for several years after age 70 (27).   133 
Using radiological features to predict risk is not foreign to radiology with well recognised guidelines 134 
for the management of incidental nodules identified at CT scanning (28).  Tabar has documented the 135 
common mammographic features associated with high grade invasive cancers (29) and Alexander 136 
with low grade invasive cancers (30) but using this to reduce the number of recalls or identifying 137 
cancers not to investigate has never been part of the screening programme culture mainly because 138 
our current technology and knowledge is not good enough to perform this task with enough 139 
specificity or certainty.  This dilemma is best illustrated by the problem of microcalcification.  The 140 
majority of calcification that we biopsy turns out to be benign and the more we identify and biopsy 141 
the larger number of ‘incidental’ pathological risk or low risk malignant lesions are found (31) 142 
however this should be balanced against the fact that a few of these lesions contain small high grade 143 
invasive disease (the cancers we really need to pick up). High rates of DCIS detection are associated 144 
with higher rates of small high-grade invasive cancer detection (32,33) and lower interval cancer 145 
rates (31) 146 
Artificial intelligence, machine learning and big data sets are seen to be one way forward (34, 35). 147 
Currently the emphasis is to improve the predictive accuracy of screening by reducing the recall rate 148 
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to reduce harm (36). Even if they were able to  could dichotomise mammographic abnormalities by 149 
risk with potential support from functional imaging which preferentially images metabolically active 150 
disease (37), the whole ethos and purpose of screening would need to be changed. 151 
Radiologists and screen readers are performance monitored by their cancer detection rates (38) and 152 
haunted by their missed cancers if not hunted through the legal system with fears of missing a 153 
diagnosis and of litigation being a major cause of both over investigation and thus over diagnosis 154 
(39) 155 
With the exception of tomosynthesis, which can reduce recall as well as increasing cancer detection 156 
(40) new technology for screening or supplemental screening for higher risk women is always 157 
introduced to find more cancer (41).  Unfortunately, early publications do not have long enough 158 
follow up to report interval cancers and do not usually make any effort to distinguished high risk 159 
from low risk disease.  Reporting more small cancers and fewer node positive cancers (probably 160 
those most likely to be over diagnosed) is not a proper substitute for reporting grade and biological 161 
marker characteristics. 162 
Patient expectation and knowledge will need a radical overhaul as we will need to explain that 163 
screening is not about finding cancer but about finding killing cancer which means that in the very 164 
extreme scenario an abnormality is identified either by the film reader or machine reader that looks 165 
like a low risk cancer and it is just ignored and allowed to grow on the principle ‘that what you don’t 166 
know about can’t harm you’. Alternatively, the woman is recalled to explain that she probably does 167 
have a cancer but its’ not an ‘important one’ so we do not intend to confirm this by biopsy or other 168 
imaging, which might throw up another ‘false positive’ lesion, we are just going to recommend 169 
active monitoring. At least in this case the woman can make an informed choice. 170 
 171 
Reducing over treatment. 172 
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De-escalation of treatment is not new and there has been a long and distinguished history of 173 
progressive reduction in the aggressiveness of surgical treatment of breast cancer.  Fisher showed 174 
that, after 25 years of follow up, radical mastectomy offered the same survival as simple 175 
mastectomy (42). He further showed in NSABP -06 that, at 20 years, local surgery with radiotherapy 176 
was equivalent to mastectomy, for invasive cancer less than 4 cm in size (43). In more recent years 177 
the recommendations for the amount of normal breast tissue surrounding a cancer (surgical margin) 178 
has steadily reduced (44). 179 
Management of the axilla has similarly changed. Removal of all axillary nodes via axillary lymph node 180 
dissection (ALND) was considered to be standard treatment (45) but is associated with significant 181 
morbidity (46). It was replaced by Sentinel Lymph Node Biopsy (SLNB) (47,48) and then in 2011 the 182 
ACOSOG Z001115 trial (49) showed that in a specific group of women with a low burden of axillary 183 
disease identified at sentinel lymph node sampling they do not gain any additional benefit from 184 
proceeding to therapeutic axillary node clearance. Although there is still controversy regarding the 185 
results and other trials are currently in progress (50) this trial has revolutionised the management of 186 
the axilla.  Unfortunately, guidance for Pre-operative staging of the axilla has not caught up (51) and 187 
routine staging with ultrasound and needle biopsy of abnormal nodes has led to reports of between 188 
38% (52) and 47%( 53) of women with positive nodes on needle biopsy being over treated with 189 
ALND. 190 
  191 
The addition of radiotherapy after conservation surgery reduces relapse rate by about half and 192 
mortality by a sixth (54) but at the cost of significant side effects including cardiac toxicity and up to 193 
a third of women reporting long term cosmetic problems. (55). Reducing the number and duration 194 
of treatments to deliver the same dose from 5 weeks to 3 weeks and more recently 1 week reduces 195 
side effects without effecting outcomes however the results of accelerated partial breast 196 
radiotherapy are less clear cut. (57).  Given that current local recurrence rates are so low the most 197 
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recent trial to be launched is PRIMETIME a case cohort study which is adding a single proliferation 198 
marker to standard clinical features, ER PR and HER2 to identify women at very low risk of local 199 
recurrence who will receive a recommendation to omit radiotherapy (55) 200 
Identifying a group of breast cancer patients who could avoid surgery and be offered active 201 
monitoring  202 
DCIS has been described as a disease of screening (18), as it classically present as mammographic 203 
calcifications rather than a mass lesion and it is considered to be a non- obligate precursor of 204 
invasive cancer with an unknown course of progression.  When treated it has a very low breast 205 
cancer specific mortality (57).  The addition of radiotherapy after local surgery reduces local 206 
recurrence rates (58), particularly in women with close margins (59). Of those women who have 207 
subsequent events nearly half are invasive and there is some evidence that death from breast cancer 208 
although rare is usually/always preceded by an invasive event (57). The challenge is to identify those 209 
women with DCIS who are unlikely to recur or alternatively find a marker which can predict 210 
recurrence at diagnosis or predict recurrence before it becomes a risk for death. More recent 211 
prognostic scores to determine who will benefit from radiotherapy require validation if they are to 212 
gain widespread acceptability. (60) 213 
Histopathology currently divides DCIS into three grades on morphological grounds and there is good 214 
evidence that low-grade disease recurs late (61) and more frequently as low grade invasive cancer 215 
(62-64) and that if a higher grade invasive disease occurs it is likely to be a new primary.  This is 216 
supported by Sagara using the SEER database (65) who showed no significant survival benefit of 217 
breast surgery for low‐grade DCIS with a 10‐year overall survival of 91% in the non‐surgery group 218 
and 87.9% in the surgery group and 10‐year breast cancer specific survival of 93.4% in the non‐219 
surgery group and 98.8% in the surgery group. 220 
Histopathological grading is not perfect (66-68) and at least in trials investigating the benefits of 221 
radiotherapy and hormone treatment, which might of course have biased selection, there does 222 
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seem to be a difference in grading between countries with the USA and Europe having larger 223 
numbers of lower grade disease than in the UK screening programme.  (69-70) 224 
This epidemiological evidence is now supported by genomic and transcriptional evidence. The 225 
traditional model of breast cancer progression with increasing numbers of molecular activation of 226 
oncogenes and inactivation of suppressor genes has now been shown to be a great deal more 227 
complex with different multiclonal evolutions being related to specific metastatic sites (71) There is 228 
now increasing evidence that there are likely to be 2 distinct evolutionary pathways for low and 229 
high-risk disease.  A low risk pathway: Flat epithelial atypia /atypical ductal hyperplasia/low grade 230 
DCIS /low grade invasive disease pathway primarily characterised by frequent loss of 16q. A high-risk 231 
pathway: High grade DCIS progressing to high grade invasive disease where there is infrequent loss 232 
of 16q accompanied by more complex changes with frequent loss of 13q with multiple high-level 233 
gene amplification (72) 234 
 Internationally the breast cancer community has taken the plunge and followed the example of 235 
urologists treating prostate cancer (the ProtecT trial) (73).  In the UK the Low RISk DCIS trial (LORIS) 236 
recruiting its first patient in October 2014 (74), LOw Risk DCIS (LORD) in the Europe (75) and 237 
Comparison of Operative to Monitoring and Endocrine Therapy for Low Risk DCIS (COMET) in the 238 
America (76) are open for recruitment.  The trials are fundamentally similar recruiting women with 239 
“low risk” DCIS presenting with microcalcification and offering randomisation to conventional 240 
surgical treatment verses active monitoring with primary outcomes of ipsilateral breast cancer free 241 
survival at a variety of time points. 242 
These trials have not been simple to set up, like ProtecT (73) before it, they have been slow to 243 
recruit in the initial stages as the medical profession need to change ingrained behaviour of offering 244 
surgery and patients have been brought up to expect “cancer” to be removed. (77)  It is difficult to 245 
sell the concept that active monitoring is about avoiding treatment until it is necessary and that 246 
treatment at that point can be offered when cure can still be offered. Providing safety nets for both 247 
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professionals and patients is key to success without excluding too many to make recruitment 248 
impossible or making follow-up so intrusive that the primary surgery would have been preferable. 249 
Securing a solid diagnosis at presentation prior to randomisation relies on biopsy techniques that 250 
provide adequate material to reduce the risk of missing something serious (in the case of 251 
microcalcification high grade or invasive disease).  Each trial has a different strategy to reduces this 252 
risk, all requiring vacuum assisted biopsy but LORIS, the UK trial, has added central pathology review 253 
so that at least there is consistency in the diagnosis of “low risk” disease. The hardest paradox is the 254 
presence of extensive calcification where on one hand there is professional anxiety about missing 255 
high grade DCIS or an invasive cancer somewhere in the area of concern verses the fact that the 256 
patient concerned has the “most to lose” in terms of the conventional extensive surgical options 257 
including mastectomy. 258 
Active monitoring is equally hard to balance as there is no good evidence about how these lesions 259 
change over time, presumably they will grow but this is not necessarily a predictor of progression to 260 
invasion, so a balance must be drawn between continuous monitoring verses regular intervention 261 
with further biopsies.  All trials have defined criteria for intervention to reduce the chances that 262 
active monitoring by mammography does not turn into active monitoring by vacuum assisted biopsy. 263 
As the three trials will provide a cohort of women managed without surgery Cancer Research UK and 264 
Dutch Cancer Society has funded a joint project preventing unnecessary breast cancer treatment 265 
PRECISION (78) to trying to identify imaging, biological and genetic markers for risk of recurrence 266 
from a series of historical treated cohorts that will then be prospectively validated in the new trials. 267 
Having committed to no surgical trials for DCIS the next step is to consider future trials for ‘low risk’ 268 
invasive cancer. We have good follow up data suggesting conventional treatment of tubular cancers 269 
is associated with an excellent prognosis. In Rakha’s series of 102 cases all distant recurrences 270 
followed on from the development of a second higher grade cancer (79). We also know that local 271 
recurrence rates are now very low (55) and adding proliferation markers to conventional markers 272 
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could well increase confidence. Just leaving these cancers to active monitoring is one choice. 273 
Minimally invasive image guided percutaneous ablation is still in its infancy but there are multiple 274 
small trials, with a wide range of tumour sizes, suggesting high rates of technical success with low 275 
complication rates but only 75% ‘complete ablation’. (80).  We must of course resist the temptation 276 
to replace relatively simple low risk surgery with expensive high technology imaging because we can. 277 
What do we need to do to prepare for this brave new world? 278 
Firstly, we need to be open and honest about the screening programme and start to change the 279 
pervasive publicity around cancer. Personalised medicine is not just about more more more, the 280 
new wonder drug and magic bullet it is also about cancer not being one disease, it’s a rainbow. We 281 
do have new treatments for the red end but there are lots of cancers at the blue end that don’t need 282 
treating in a hurry, under artificial politically driven waiting time targets, and might need less or even 283 
no treatment at all. This is not a new covert way of saving money for social care. 284 
Secondly, we need to ensure that every one of our patients has the opportunity to be involved in a 285 
trial, as the late Professor Adele Francis was very fond of telling her surgical colleagues ‘it’s not good 286 
enough to just keep on doing what we have always done’ 287 
Finally, we need to optimise the enormous data base that is NBSS, link it to cancer registry and all 288 
the digital images stored on PACS and if necessary start storing the ‘raw’ not for processing data, 289 
which is needed for machine learning. Then start using the information to design the trials of the 290 
future to maximise benefit and minimise harm. 291 
 292 
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Figure captions 520 
 521 
Figure 1 Cancers do not all grow at the same rate 522 
Cancer 1: fast growing unlikely to be picked up by screening 523 
Cancer 2: slow growing but progressive will benefit from screening 524 
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Cancer 3: very slow growing likely to be over diagnosed and over treated 525 
Cancer 4: non-progressive 526 
 527 
Figure 2  Length bias: the fixed time interval between screens means that it is more likely that the 528 
slow growing tumours will be detected. The length of the arrows represents the time between 529 
detectability at screening and the clinical onset. The grey arrows represent screen detected cancers 530 
the black one interval cancers. After Sardanelli (10) 531 
 532 
Fig 3 Screening and over diagnosis: Comparison of line A (no screening) and line B (screening) shows 533 
a clear increase in survival not only because of early diagnosis but prolongation of life. Line C (over 534 
diagnosis) the over diagnosis is clear cut if an individual dies from other causes before the ‘point of 535 
clinical onset’ but death from other causes after this point could either be the result of successful 536 
treatment or over diagnosis of a ‘non-killing’ cancer. 537 
 538 
Figure 4: Pictogram from ‘Breast Cancer Now’ showing breast screening key facts (24) 539 
 540 
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